title: Favorable early and long-term prognosis following coronary bypass surgery therapy for myocardial infarction: results of a multicenter trial. TAMI Study Group.
abstract: Coronary bypass surgery was performed before hospital discharge on 82 (21%) of 386 consecutive patients enrolled in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) multicenter trial of intravenous tissue plasminogen activator and coronary angioplasty for acute myocardial infarction. Time from infarct symptom onset to coronary bypass surgery was 7.3 +/- 1.9 hours for 24 patients operated upon on an emergency basis and 9.3 +/- 5.2 days for 58 patients having late in-hospital surgery. There were no operative deaths and five in-hospital deaths in the surgical group, all of which occurred in patients with preoperative cardiogenic shock. Although patients in the surgical group were older (59.7 +/- 10.4 years versus 54.9 +/- 10.2 years; p = 0.03), had more extensive coronary artery disease (42% three-vessel disease versus 11%; p = 0.001), and had a higher incidence of anterior wall myocardial infarction (48% versus 39%; p = 0.02), in-hospital mortality for the surgical group (6%) was similar to that in 301 patients not undergoing surgery (7%) in this trial. For patients discharged from the hospital, mortality at 1 year was 2.5% in the surgical group and 1.8% in patients not having coronary bypass surgery before hospital discharge. At a 1 year follow-up, there were no significant differences in the frequency of cardiac or noncardiac-related hospitalizations or in event-free survival between surgical and nonsurgical groups. The majority of patients in both groups considered themselves to be in excellent or good condition. Coronary bypass surgery can be performed with low morbidity and mortality rates in close temporal association to acute myocardial infarction.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Christ Hospital, Cincinnati, OH.
authors.forename: D J
authors.initials: DJ
authors.lastname: Kereiakes
authors.forename: E J
authors.initials: EJ
authors.lastname: Topol
authors.forename: B S
authors.initials: BS
authors.lastname: George
authors.forename: C W
authors.initials: CW
authors.lastname: Abbottsmith
authors.forename: R S
authors.initials: RS
authors.lastname: Stack
authors.forename: R J
authors.initials: RJ
authors.lastname: Candela
authors.forename: W W
authors.initials: WW
authors.lastname: O'Neill
authors.forename: L C
authors.initials: LC
authors.lastname: Anderson
authors.forename: R M
authors.initials: RM
authors.lastname: Califf
mesh_terms: D000800:Angioplasty, Balloon; D001803:Blood Transfusion; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass / Q000401:mortality; D004630:Emergencies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000188:drug therapy / Q000601:surgery* / Q000628:therapy; D011379:Prognosis; D011788:Quality of Life; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
chemical_list: D010959:Tissue Plasminogen Activator